IP Library › Granted Patent US 7,217,800
Granted Patent B2
US 7,217,800 · App. 10/932,004 · Granted May 15, 2007

Peptide leukotriene receptor

Assignees: Astellas Pharma Inc.; Helix Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,217,800
App. No.
10/932,004
Granted
May 15, 2007
Kind
B2
Abstract

A cDNA encoding a novel LTC 4 receptor has been isolated. Provision of the novel protein, an LTC 4 receptor, enabled binding experiments using the LTC 4 . By screening for compounds that modulate LTC 4 receptor activity based on these binding experiments, development of drugs targeting the LTC 4 receptor becomes possible.

Claims (2)

1. An antibody against

a protein comprising an amino acid sequence of any one of SEQ ID NO: 2, 18, and 22.

Assignments (1)
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
Priority Claims (1)
JP 11-259986 · Sep 14, 1999 · national
Continuity (2)
Division 0997960300
Related Publication 20050037968A1 · Feb 17, 2005